CD93 is a transmembrane glycoprotein primarily expressed on endothelial cells that plays critical roles in angiogenesis, inflammation, and immune regulation. The protein contains C-type lectin-like and EGF-like domains 1 and functions as a receptor for defense collagens including C1q, surfactant protein A, and mannose-binding lectin, facilitating phagocytosis and apoptotic cell clearance 2. CD93 exerts its angiogenic function through multiple pathways: it associates with β-dystroglycan to trigger SRC-dependent phosphorylation and CBL recruitment, promoting endothelial cell migration 3, and acts as a receptor for the ligands multimerin-2 and IGFBP7, both playing non-redundant roles in endothelial function 4. In pathological contexts, CD93 is significantly upregulated in tumor-associated endothelial cells where it promotes abnormal vascular development; blockade of the CD93/IGFBP7 interaction normalizes tumor vasculature, enhances drug delivery, and improves immunotherapy efficacy 4. Beyond angiogenesis, CD93 is expressed in hematopoietic stem cells, immune cells, and platelets, with roles in inflammation, cardiovascular disease, and autoimmune disorders 5. A CD93-enriched HSC/MPP subset exhibits enhanced stem cell properties in fetal liver niches 6. Overall, CD93 represents a promising therapeutic target for cancer, cardiovascular disease, and inflammatory conditions.